Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22408689 | 0.80 | LMNA (0.53) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3000414 | 0.80 | LMNA (0.53) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28079080 | 0.78 | LMNA (0.51) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1527119 | 0.70 | TSHR (0.39) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3806350 | 0.70 | ERN1 (0.42) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL480683 | 0.70 | LMNA (0.39) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12766925 | 0.67 | LMNA (0.40) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3189250 | 0.66 | TSHR (0.44) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL566202 | 0.66 | GAA (0.43) | LMNATSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1689852 | 0.66 | LMNA (0.39) | LMNATSHRHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20200399242-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | LMNA 1717/4885TSHR 4310/4885HTT 3861/4885 |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | LMNA 1400/4885TSHR 2925/4885HTT 2188/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | LMNA 732/4885TSHR 3203/4885HTT 2395/4885 |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | LMNA 1618/4885TSHR 3071/4885HTT 2112/4885 |
| US-20200399242-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | LMNA 1038/4885TSHR 1700/4885HTT 2260/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | LMNA 1266/4885TSHR 3166/4885HTT 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.